[1] Siegel RL, Miller KD and Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
[2] Anglesio MS, Carey MS, Köbel M, et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic oncology. 2011;121:407-415.
[3] Glasspool RMand McNeish IA. Clear cell carcinoma of ovary and uterus. Curr Oncol Rep. 2013;15:566-572.
[4] del Carmen MG, Birrer Mand Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecologic oncology. 2012;126:481-490.
[5] Bennett JA, Dong F, Young RH, et al. Clear cell carcinoma of the ovary: evaluation of prognostic parameters based on a clinicopathological analysis of 100 cases. Histopathology. 2015;66:808-815.
[6] Clark TG, Stewart ME, Altman DG, et al. A prognostic model for ovarian cancer. British journal of cancer. 2001;85:944-952.
[7] Ebina Y, Uchiyama M, Imafuku H, et al. Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine. 2018;97:e11009.
[8] Liu P, Wang Y, Tong L, et al. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients. Cancer chemotherapy and pharmacology. 2015;76:1163-1171.
[9] Wu J, Fu Z, Liu G, et al. Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis. Medicine. 2017;96:e7062.
[10] Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.
[11] Ethier JL, Desautels DN, Templeton AJ, et al. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecol Oncol. 2017;145:584-594.
[12] Kwon BS, Jeong DH, Byun JM, et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. Journal of Cancer. 2018;9:1127-1134.
[13] Yoshida K, Yoshikawa N, Shirakawa A, et al. Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. Journal of gynecologic oncology. 2019;30:e85.
[14] Ocana A, Nieto-Jiménez C, Pandiella A, et al. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16:137.
[15] Dunn GP, Old LJ and Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
[16] Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1-13.
[17] Zhao Z, Zhao X, Lu J, et al. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies. Archives of gynecology and obstetrics. 2018;297:849-857.
[18] Yang Z, Gu JH, Guo CS, et al. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival of epithelial ovarian cancer: a systematic review and meta-analysis of observational studies. Oncotarget. 2017;8:46414-46424.
[19] Kim HS, Choi H-Y, Lee M, et al. Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. Cancer research and treatment: official journal of Korean Cancer Association. 2016;48:250-258.
[20] Zhang H, Lu J, Lu Y, et al. Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma. PloS one. 2017;12:e0177520.
[21] Sierzega M, Lenart M, Rutkowska M, et al. Preoperative Neutrophil-Lymphocyte and Lymphocyte-Monocyte Ratios Reflect Immune Cell Population Rearrangement in Resectable Pancreatic Cancer. Ann Surg Oncol. 2017;24:808-815.
[22] Lin Y, Liu Z, Qiu Y, et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: A systematic review and meta-analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2018;44:1494-1503.
[23] Zhu LR, Li J, Chen P, et al. Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2016;18:178-188.
[24] Li H, Zhao S, Jing Z, et al. Combination of D-dimer and carcinoembryonic antigen levels as a predictive and prognostic biomarker in advanced colorectal cancer patients. Journal of cellular biochemistry. 2018.
[25] Yamada Y, Kawaguchi R, Iwai K, et al. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2020;40:102-106.
[26] Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. British journal of cancer. 2007;96:290-295.